<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04250129</url>
  </required_header>
  <id_info>
    <org_study_id>2018-03</org_study_id>
    <nct_id>NCT04250129</nct_id>
  </id_info>
  <brief_title>SENTINEL LYMPH NODE BIOPSY AFTER NEOADJUVANT CHEMOTHERAPY</brief_title>
  <acronym>NEOSENTITURK</acronym>
  <official_title>IS SENTINEL LYMPH NODE BIOPSY WITH RADIOTHERAPY ALONE WITHOUT AXILLARY LYMPH NODE DISSECTION SAFE FOLLOWING NEOADJUVANT CHEMOTHERAPY IN INITIALLY CLINICALLY AXILLA POSITIVE PATIENTS: NEOSENTITURK-TRIAL/MF-18-03</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation of Breast Diseases Societies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation of Breast Diseases Societies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Omitting axilary lymph node dissection (ALND) following SLNB with residual cancer in patients
      with locally advanced disease after neoadjuvan chemotherapy (NAC) is still controversial. In
      this study, the investigators evaluated factors affecting local recurrence and outcome in
      patients with locally advanced breast cancer (LABC), who underwent sentinel lymph node (SLN)
      with or without ALND after NAC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients with clinically positive axilla will undergo neoadjuvant chemotherapy. Axillary
      fine needle aspiration biopsy or Trucut biopsy is mandatory.

      All patients with clinically node negativity (physical exam, USG, and/or MRI, PET-CT) after
      Neoadjuvant Chemotherapy (NAC) will be considered for SLNB with any technique (blue dye
      alone, radionuclide alone or both combined) and any breast surgery (mastectomy or breast
      conservation). PET-CT and MRI are not mandatory. PE and USG and/or MRI are preferred. At
      least, 2 sentinel lymph nodes will be obtained. Intraoperative evaluation of SLNs is
      recommended.

      All patients with clinally-negative axilla and underwent SLNB will be included into the
      study:

        1. SLNB (-) &amp; RT

        2. SLNB (+) &amp; RT

        3. SLNB (+) &amp; ALND &amp; RT Radiotherapy details will be announced as supplementary
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Local recurrence free survival</measure>
    <time_frame>January 2023</time_frame>
    <description>Breast and axillary recurrence rates</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>January 2023</time_frame>
    <description>Local recurrence and distant metastasis rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>January 2023</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Sentinel Lymph Node</condition>
  <arm_group>
    <arm_group_label>SLNB (-)&amp;level 1-3 RT</arm_group_label>
    <description>SLNB (-)&amp;level 1-3 RT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLNB (+)&amp;level 1-3 RT</arm_group_label>
    <description>SLNB (+)&amp;level 1-3 RT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLNB(+)&amp;ALND&amp;level 3 RT (+/-level 1-2)</arm_group_label>
    <description>SLNB(+)&amp;ALND&amp;level 3 RT (+/-level 1-2)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with clinically positive axilla will undergo neoadjuvant chemotherapy. All
        patients with clinically node negativity (physical exam, USG, and/or MRI, PET-CT) after
        Neoadjuvant Chemotherapy (NAC) will be considered for SLNB with any technique (blue dye
        alone, radionuclide alone or both combined) and any breast surgery (mastectomy or breast
        conservation). PET-CT and MRI are not mandatory. PE and USG and/or MRI are preferred. At
        least, 2 sentinel lymph nodes will be obtained. Intraoperative evaluation of SLNs is
        recomended.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        T0-4, N1-3, M0

        Exclusion Criteria:

        Inflammatory breast cancer, pregnant patients Patients with metastatic disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neslihan Cabioglu, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul University, Istanbul Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hasan Karanlik</last_name>
    <role>Study Director</role>
    <affiliation>Istanbul University Institute of Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guldeniz Karadeniz Cakmak</last_name>
    <role>Study Chair</role>
    <affiliation>Bulent Ecevit University Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neslihan Cabioglu, Prof</last_name>
    <phone>+905325057724</phone>
    <email>ncabioglu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hasan Karanlik, Prof</last_name>
    <phone>+905324025354</phone>
    <email>hasankaranlik@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istanbul University Institute of Oncology</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hasan Karanlik, Prof</last_name>
      <phone>+905324025354</phone>
      <email>hasankaranlik@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul University Istanbul Faculty of Medicine</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neslihan Cabioglu, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Abdullah Igci, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mahmut Muslumanoglu, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vahit Ozmen, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bulent Ecevit University Faculty of Medicine</name>
      <address>
        <city>Zonguldak</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guldeniz Karadeniz Cakmak, Prof</last_name>
      <phone>05323371860</phone>
    </contact>
    <contact_backup>
      <last_name>Guldeniz Karadeniz Cakmak</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sentinel lymph node biopsy, Neoadjuvan chemotherapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

